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Introduction
Acute ischemic stroke is one of the severe diseases, 
considering the fifth leading cause of mortality and 
morbidity in the United States. It reported that 1 of 
every 20 persons is dying due to this disease, and every 4 
minutes, someone dies due to stroke.1-4 Timely diagnosis 
results from proper history taking and neurological 
examinations, but still, there is an active role for para-
clinical and radiological evaluation so can make the 
diagnosis, prognosis, and outcome prediction.5-9 
Investigations have been conducted to assess the 
probable role of serum biomarkers for various aspects 
of stroke subject, from diagnosis to outcome prediction, 
and research is still on. Neuron-specific enolase (NSE) 
is the one, probably taken into consideration more than 
the others. It is a glycolytic catalyze enzyme, present in 
neuronal, neuroendocrine tissues, and cerebrospinal 
fluid (CSF).10 Kansal et al reported that its measurement 
in CSF might assist in the diagnosis of neurodegenerative 
diseases, such as Creutzfeldt-Jacob and ischemic stroke.11 
Recently, studies provide evidence regarding the possible 
correlation between ischemic stroke and elevation of 
serum NSE.12-14 Anand et al. investigated time to increase 
the serum level of NSE in the case of middle cerebral 
artery occlusion.15 Singh et al reported that NSE level is 
significantly high in patients with severe neurological 
deficit than the groups of mild or moderate.16 Besides, 
the study of Lu et al demonstrates that after treatment of 
ischemic stroke, there is a strong correlation between the 
reduction of NSE serum level and good prognosis.17
It seems that the role of serum biomarkers, including 
NSE, for diagnosis of stroke has been previously taken 
into account; but it is still vague. In this systematic review 
and meta-analysis, we aim to assess the diagnostic value 
of serum NSE level in patients with acute ischemic stroke, 
to weigh whether its level could consider as a diagnostic 
factor or not?
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Abstract
Background: We aim to assess the predictive value of serum neuron-specific enolase (NSE) level in 
patients with acute ischemic stroke referring to the emergency department.
Methods: This systematic review and meta-analysis performed, considering the PRISMA and MOOSE 
statement guidelines. A computerized literature search of the known medical database conducted by 
using the relevant keywords. We included studies published before November 2016 in which stroke 
patients compared with non-stroke controls and also studies evaluating the serum levels of NSE in the 
study groups. Statistical analysis was pooled in a random effect model analysis using the Comprehensive 
Meta-Analysis software.
Results: We included 12 articles in the qualitative and quantitative analysis, that their quality acceptable 
based on the Newcastle Ottawa Scale (NOS scale). The pooled effect estimates showed that NSE is 
significantly higher in ischemic stroke patients in comparison with their controls with a high effect 
estimate [OR 9.68, 95% CI (3.06 to 30.6)]. The effect estimate remained statistically significant under the 
fixed and random effects model.
Conclusion: Our results show higher levels of NSE in patients with stroke than in the control group, 
indicating that NSE plays a role in the diagnosis of stroke. In terms of prognosis, there is evidence 
regarding the direct and indirect relationship; and it founded that serum levels of NSE is higher in larger 
stroke volume, which needs further research.
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Methods
This systematic review and meta-analysis performed 
during 2017 with a team from Iranian and Egyptian 
researches. We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) and 
Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) statement guidelines during the preparation 
of this systematic review and meta-analysis.18,19 All 
steps performed in line with the Cochrane Handbook of 
Systematic Reviews and Meta-analysis of interventions 
and all analyses were performed in line with the equations 
recommended by Borenstein et al in the introduction to 
meta-analysis.20,21
Literature Search Strategy
A computerized literature search of the known medical 
database of PubMed, EMBASE, ISI Web of Sciences, 
CINAHL and Scopus using the following keywords: 
((Phosphopyruvate Hydratase) OR (Neuron Specific 
Enolase)) AND “Stroke”). We included studies published 
in English before November 2016 in which stroke patients 
compared with non-stroke controls and also studies 
evaluating the serum levels of NSE in the study groups.
Study Selection
Two authors independently screened the literature search 
results for relevant studies. All studies published before 
November 2016 included. In the first step, titles and 
abstracts of the retrieved records screened, and then 
full-text articles of selected papers at the first step were 
evaluated. Any disagreement between the two reviewers 
resolved by discussion with a third reviewer.
Eligibility Criteria
(1) Studies whose population was patients with stroke 
compared with non-stroke controls; (2) studies evaluating 
the serum levels of NSE in the study groups; (3) studies 
that were described as observational studies, whether 
prospective or retrospective, evaluating NSE in stroke and 
non-stroke patients. We excluded animal studies and also 
studies whose data were not reliable for analysis.
Data Extraction
Data were extracted independently by 2 reviewers to a 
uniform data extraction sheet. The extracted data includes 
(1) characteristics of the study design of included studies, 
(2) characteristics of the study population, and (3) data of 
the study outcomes. 
Risk of Bias Across Studies
To explore the publication bias across studies, we 
constructed funnel plots to present the relationship 
between effect size and precision. Evidence of publication 
bias was assessed by (1) the Egger’s regression test, and (2) 
the trim and fill method. 
Synthesis of Results
The prognostic value of NSE in stroke patients presented 
in observational studies in different formats. Studies 
reported their outcomes as (1) the mean difference and 
variance between the stroke group and the control group, 
(2) correlation coefficient between NSE and stroke, or (3) 
binary data as odds ratios with their 95% CI. The Cohen’s 
(d) effect size and its variance computed from all studies 
according to equations provided in the Introduction 
to meta-analysis. Then the Cohen’s (d) effect size was 
converted into the log point estimate (odds ratio) and 
its variance. Finally, the log (OR) and its variance were 
pooled in a random effect model analysis using the 
Comprehensive Meta-Analysis software. Heterogeneity 
assessed by the Cochrane Q test, chi-square test for the Q 
statistics distribution, and the I-square test. The trim and 
fill method was used to investigate small study effects and 
the possibility of publication bias. 
Results
Study Selection 
The primary literature search resulted in 1300 records, 
and finally, 12 articles with a total of 970 patients included 
in the meta-analysis.13,14,16,22-30 Of the excluded studies, 
there were two relevant articles (Cunningham et al31 and 
Wunderlich et al32) as they reported the effect estimates in 
figures whose data could not be extracted and were not 
reliable for analysis. The PRISMA flow diagram of the 
current study has shown in Figure 1.
Characteristics and Quality of Included Studies
Baseline characteristics of these studies summarized in 
Table 1. The quality of included studies was acceptable, 
according to the Newcastle Ottawa Scale (NOS).
The Correlation Between NSE and Stroke
Figure 2 shows the forest plot of the OR of NSE in stroke 
vs. control cases with 95% CI under the fixed and random 
effect models. The pooled effect estimates showed that 
NSE is significantly higher in ischemic stroke patients 
compared to their controls with a high effect estimate (OR 
9.68, 95% CI [3.06 to 30.6]). The effect estimate remained 
statistically significant under the fixed and random effects 
model.
Figure 3 shows the funnel plot of standard error by 
point (log) of NSE in stroke vs. control cases with the 
standard error of under the random effect model. It 
showed no evidence of publication bias. The trim and fill 
method gave the same effect estimate suggesting no small 
study effects.
Discussion
The current meta-analysis aimed to clarify whether there 
was any significant difference in NSE levels between 
stroke patients and control. Our findings show that NSE 
serum levels are considerably higher in stroke patients 
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compared to their controls.
Stroke is an emergency medical condition which 
threatens the patient’s life and causes high levels of 
disability and mortality all over the world. In response 
to stroke, brain cells produce particular changes, such as 
releasing specific neuronal markers into the circulation 
and increasing neuronal isoenzymes levels, which results 
in brain damage. The central nervous system insult is 
evaluated by several neurobiochemical markers which 
have a standard role in the diagnosis and management 
of stroke patients with neurological side effects. NSE a 
neuronal form of the intracytoplasmic glycolytic enzyme 
enolase is one of these markers. Several studies have 
verified that NSE can be discovered in the peripheral 
blood of stroke patients and could be a useful marker for 
acute ischemic stroke.
Likewise, the conclusion of our meta-analysis is in 
agreement with Anand et al15 who conducted a systematic 
review in 2005 consisted of 597 patients, and reported 
that NSE was considerably higher in stroke patients in 
comparison with control. They also showed that NSE 
significantly correlated with infarct volume, however, it 
did not correlate with functional outcome, and there was 
no clear relationship between NSE and stroke severity. 
Also, a systematic review by Ahmed et al33 confirmed that 
NSE positively correlated with subacute infarct volume. 
These results are consistent with the findings of nine out 
of the 12 included studies in the current meta-analysis, 
which showed that NSE levels were meaningfully higher 
in stroke patients than in the control group while, other 
three included studies showed no significant difference 
between NSE and control.28,34,35 This contrast might be 
explained by the slow released of NSE from damaged 
tissue to peripheral blood.
In terms of functional outcomes, included studies 
used different methods to assess functional outcomes 
such as Barthel index, Lindley scale, modified Rankin 
Scale (mRS), Glasgow Outcome Score, and activities of 
daily living scale. Three studies22,32,35 reported a notable 
correlation between NSE and functional outcome. 
Moreover, Pandey et al,14 and Bharosay et al25 concluded 
that the higher the NSE level, the more significant 
functional worsening. However, Shahrokhi et al showed no 
significant difference between NSE serum concentrations 
and clinical outcome.36 Using different evaluation scales 
and the small sample size included might explain this 
contrast.
Nine included studies14,16,22-28 used the National 
Institutes of Health Stroke Scale (NIHSS) to evaluate 
the neurological status and stroke severity. All of them 
reported a notable correlation between NIHSS scores and 
NSE levels.
Two studies reported on NSE levels at the onset 
of a stroke. Oh et al23 found that the initial NSE was 
significantly higher in stroke patients than control within 
less than 24 hours. Wunderlich et al.,32 with a total of 66 
patients, reported that NSE levels showed a first rise 2-3 
hours after onset of the first stroke symptoms, but they 
did not compare that with control levels.
Regarding infarct volume, four included studies23,28,30,32 
demonstrated a significant correlation between NSE and 
infarct volume. 
Brea et al28 involved patients with acute ischemia and 
patients with intracerebral hemorrhage and showed that 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
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Figure 1: PRISMA Flow Diagram.
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Table 1. Summary and Baseline Characteristics of the Final Included Studies






Hospitalized patients suffering from 
ischemic stroke were 103 that 51 of 
them were under control
The United Kingdom,
# male: 63; # female: 40 age 
average: 73.6.
Barthel index, mRS 
Lindley score, Infarct 
volume
In this study, NSE correlated with 
ischemic stroke, but any correlation 
between first, second, and third days did 
not exist.
Pandey et al14
200 patients suspected to ischemic 
and 50 of them were under control
India
# male: 82 above 21years old
# female: 38 above 21 years 
old
NIHSS
In this study, the patient's NSE level in 
the seventh day for the severe group was 
higher.
Hill et al22
38 patients hospitalized in 2 hospitals 
with an ischemic stroke diagnosis
Canada;
# male: 18, # female: 10
NIHSS, mRS
In this study, the NSE level for those 
suffering from AIS was higher, and it had 
a direct correlation with prognosis.
Missler et al30
Hospitalized patients for ischemic 
stroke check-in hospitals.
Germany;
# male: 32, # female: 12
Age average: 65.1
CT infarct volume
GCS at 6 months
In this study, NSE and CVA volume 
correlated, but any correlation with 
outcome was not perceived.
Zaheer et al13
75 visiting patients to check AIS, 
which approved in the second day by 
CT scan.
Germany;




In this study, NSE correlated with GCS 
and MRS of patients, and it is a prognosis 
factor.
Oh et al23
109 visiting patients suspected to AIS 
that MRI approved their CVA.
South Korea;
# male: 42, # female: 21
Age average: 64.3
NIHSS, mRS
Arrival NSE of patients directly correlated 
with the outcome of patients.
Oh et al24 All visiting patients for AIS check
South Korea;
# male: 42, # female: 39
Age average: 66.7
Lesion volume in 
MRI, NIHSS of the 
seventh-day
Serum NSE level had a direct correlation 
with CVA volume and arrival NIHSS
Bharosay et 
al25
251 suspected patients of CVA that 
150 of them suffering patients, and 
the rest considered as the controlling 
group.
India;
# male:95, # female: 55
Patients age:  between 35 to 85
NIHSS
In this study; Serum NSE level of the 
severe group was higher than others
Kaca et al26
71 patients suffering from AIS 
included in the study, and 41 of them 
considered as the controlling group
Poland;
# male: 42, # female: 29
Age average: 71
NIHSS, Barther score, 
mRS
In this study; NSE with stroke volume and 
patient's prognosis d not correlated.
Gonzalez et 
al27
61 hospitalized patients with ischemic 
stroke diagnosis.
Cuba;
# male: 33, # female: 31
Age average: 65.6
NIHSS
In this study; NSE correlated with 
patients' prognosis
Brea et al28
224 hospitalized patients with 
ischemic stroke and hemorrhagic 
diagnosis
Spain;
# male: 114, # female: 110
Age average: 69.6
NIHSS, mRS
In this study; it determined that serum 
NSE level in hemorrhagic patients is 
higher and also its level is correlated 
with ischemic and hemorrhagic patients 
prognosis
Singh et al16
100 patients suffering from CVA that 
their NSE checked 72 hours later.
India NIHSS
In this study; serum NSE level was 
correlated with NIHSS
Abbreviations: NSE, neuron-specific enolase; AIS, acute ischemic stroke; CVA, cerebrovascular accident; NIHSS, National Institutes of Health Stroke Scale; 
GCS, Glasgow coma scale; mRS, modified Rankin Scale.
Figure 2. Forest Plot of the Odds Ratio of NSE in Stroke vs. Control CASES With 95% CI Under the Fixed and Random Effect Models.
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higher levels of NSE were associated with poor functional 
outcome in both acute ischemia and intracerebral 
hemorrhage patients. Pandey et al14 stratified stroke 
into different subtypes and showed that patients with 
hemorrhagic stroke had higher levels of NSE than patients 
with ischemic stroke. These results are supported by the 
results of Andersen et al37 who showed that NSE was more 
in patients with hemorrhagic stroke than infarct stroke.
Strength Points
The present meta-analysis demonstrated no heterogeneity 
regarding the significant effect of NSE on stroke between 
the included studies. The effect estimate was consistent 
under the fixed and random effects model. Additionally, 
the funnel plot method showed no evidence of publication 
bias. The trim and fill method gave the same effect 
estimate of meta-analysis, suggesting no small study 
effects, this indicates that our results are highly consistent 
and reliable.
Limitations
Study limitations come back to the variations between the 
included studies in defining the period of acute stroke, the 
measures of functional outcomes, the severity of stroke 
scales, and the methods of NSE concentrations. Also, 2 
studies were excluded due to unreliable data extraction 
from them, as they reported the effect estimates in figures 
whose data could not be extracted and were unreliable for 
analysis. 
Conclusion
Our results show higher levels of NSE in patients with 
stroke than in the control group, indicating that NSE plays a 
role in the diagnosis of stroke. In terms of prognosis, there 
is evidence regarding the direct and indirect relationship; 
and it founded that serum levels of NSE is higher in larger 
stroke volume, which needs further research.
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